BIOMAT Database Logo BIOMAT Database Logo

BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports. 2019

Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
Department of Dermatology, Gustave Roussy, 114 Rue Edouard-Vaillant, 94800, Villejuif, France. Electronic address: audrey.melin1@gmail.com.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010091 Oximes Compounds that contain the radical R2C Aldoximes,Hydroxyimino Compounds,Ketoxime,Ketoximes,Oxime,Compounds, Hydroxyimino
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons

Related Publications

Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
Response of metastatic acral melanoma with exon 11 BRAF G469A mutation to BRAF/MEK inhibition.
April 2022, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
Inhibition of BRAF and MEK in BRAF-mutant melanoma.
August 2015, Lancet (London, England),
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
June 2015, Expert opinion on pharmacotherapy,
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review.
January 2022, Frontiers in pharmacology,
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition.
September 2021, Cancers,
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
Ansprechen eines metastasierten akrolentiginösen Melanoms mit Exon-11-BRAF-G469A-Mutation auf BRAF/MEK-Inhibition.
April 2022, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
July 2013, Science translational medicine,
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
June 2019, Nature medicine,
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.
September 2021, Oncogene,
Audrey Melin, and Emilie Routier, and Hubert Tissot, and Etienne Rouleau, and Caroline Robert
BRAF and MEK inhibition in melanoma.
April 2015, Expert opinion on drug safety,
Copied contents to your clipboard!